Literature DB >> 19943031

[Clinical aspects and epidemiology of uncomplicated cystitis in women. German results of the ARESC Study].

F M E Wagenlehner1, C Wagenlehner, O Savov, L Gualco, G Schito, K G Naber.   

Abstract

OBJECTIVE: Uncomplicated cystitis in women is among the most frequent infections in the community setting. The German results of the international ARESC Study are reported concerning clinical aspects, epidemiology, and antimicrobial susceptibility of uropathogens. PATIENTS AND METHODS: Patients between 18 and 65 years of age with symptoms of uncomplicated cystitis were consecutively enrolled and investigated clinically including urinalysis and urine culture. Uropathogens were identified and their susceptibility was tested for nine antimicrobials
RESULTS: In Germany a total of 442 patients were enrolled and 412 were eligible. A positive urine culture (cfu>/=10(4)/ml) was found in 335 (81.3%); 325 (97.1%) of them had a monoinfection. A total of 317 uropathogens were further analyzed in a central laboratory (Genua). Escherichia coli was the most frequent (76.7%), followed by Proteus mirabilis (4.7%), Staphylococcus saprophyticus (2.8%), Klebsiella pneumoniae (2.5%), enterococci (2.5%), and Staphylococcus aureus (2.2%). E. coli showed the highest rate of susceptibility to fosfomycin (97.9%) followed by mecillinam (97.5%), nitrofurantoin (95.4%), and ciprofloxacin (95.4%). The lowest rate was found for ampicillin (59.2%) followed by cotrimoxazole (74.0%). For the total spectrum the order was fosfomycin (96.1%), mecillinam (97.5%), ciprofloxacin (92.3%), and nitrofurantoin (86.3%). The lowest rates were found again for ampicillin (56.6%) and cotrimoxazole (73.9%).
CONCLUSIONS: Fosfomycin, mecillinam (not available in Germany), and nitrofurantoin have preserved their in vitro activity and are suitable for empiric therapy. Because of increasing resistance rates cotrimoxazole (trimethoprim) and fluoroquinolones are generally not recommended as first-choice drugs for empiric therapy of female patients with uncomplicated cystitis.

Entities:  

Mesh:

Year:  2010        PMID: 19943031     DOI: 10.1007/s00120-009-2145-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  30 in total

1.  Survey on antibiotic usage in the treatment of urinary tract infections.

Authors: 
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.

Authors:  A Iravani; I Klimberg; C Briefer; C Munera; S F Kowalsky; R M Echols
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

3.  Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women.

Authors:  Kalpana Gupta; Thomas M Hooton; Pacita L Roberts; Walter E Stamm
Journal:  Arch Intern Med       Date:  2007-11-12

Review 4.  Urinary tract infection in diabetes.

Authors:  Lindsay E Nicolle
Journal:  Curr Opin Infect Dis       Date:  2005-02       Impact factor: 4.915

5.  Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines.

Authors:  G Fadda; G Nicoletti; G C Schito; G Tempera
Journal:  J Chemother       Date:  2005-06       Impact factor: 1.714

6.  A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women.

Authors:  M A Minassian; D A Lewis; D Chattopadhyay; B Bovill; G J Duckworth; J D Williams
Journal:  Int J Antimicrob Agents       Date:  1998-04       Impact factor: 5.283

Review 7.  Epidemiology of urinary tract infections: incidence, morbidity, and economic costs.

Authors:  Betsy Foxman
Journal:  Am J Med       Date:  2002-07-08       Impact factor: 4.965

8.  Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women.

Authors:  K G Naber; E M Koch
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

9.  Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.

Authors:  Kurt G Naber; Giancarlo Schito; Henry Botto; Juan Palou; Teresita Mazzei
Journal:  Eur Urol       Date:  2008-05-21       Impact factor: 20.096

Review 10.  Why fosfomycin trometamol as first line therapy for uncomplicated UTI?

Authors:  G C Schito
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

View more
  14 in total

1.  [Infections due to multidrug-resistant pathogens : Pathogens, resistance mechanisms and established treatment options].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-10       Impact factor: 1.041

2.  [New S3 guidelines "uncomplicated urinary tract infections"].

Authors:  F M E Wagenlehner; W Vahlensieck; K G Naber
Journal:  Urologe A       Date:  2011-02       Impact factor: 0.639

3.  Antibiotic-Resistant E. coli in Uncomplicated Community-Acquired Urinary Tract Infection.

Authors:  Anja Klingeberg; Ines Noll; Niklas Willrich; Marcel Feig; Dagmar Emrich; Edith Zill; Annegret Krenz-Weinreich; Wiltrud Kalka-Moll; Klaus Oberdorfer; Guido Schmiemann; Tim Eckmanns
Journal:  Dtsch Arztebl Int       Date:  2018-07-23       Impact factor: 5.594

4.  Uncomplicated Bacterial Community-Acquired Urinary Tract Infection in Adults.

Authors:  Jennifer Kranz; Stefanie Schmidt; Cordula Lebert; Laila Schneidewind; Guido Schmiemann; Florian Wagenlehner
Journal:  Dtsch Arztebl Int       Date:  2017-12-15       Impact factor: 5.594

Review 5.  [Urinary tract infections in the elderly].

Authors:  N Mirsaidov; F M E Wagenlehner
Journal:  Urologe A       Date:  2016-04       Impact factor: 0.639

Review 6.  [Urinary tract infections : What has been confirmed in therapy?]

Authors:  J Marcon; C G Stief; G Magistro
Journal:  Internist (Berl)       Date:  2017-12       Impact factor: 0.743

7.  Surveillance of multidrug resistant uropathogenic bacteria in hospitalized patients in Indian.

Authors:  Monali Priyadarsini Mishra; Nagen Kumar Debata; Rabindra Nath Padhy
Journal:  Asian Pac J Trop Biomed       Date:  2013-04

Review 8.  [National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients].

Authors:  F M E Wagenlehner; G Schmiemann; U Hoyme; R Fünfstück; E Hummers-Pradier; M Kaase; E Kniehl; I Selbach; U Sester; W Vahlensieck; D Watermann; K G Naber
Journal:  Urologe A       Date:  2011-02       Impact factor: 0.639

Review 9.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

10.  Uncomplicated urinary tract infections.

Authors:  Florian M E Wagenlehner; Udo Hoyme; Martin Kaase; Reinhard Fünfstück; Kurt G Naber; Guido Schmiemann
Journal:  Dtsch Arztebl Int       Date:  2011-06-17       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.